Friday, July 10, 2026

pharma · Malignant Pleural Mesothelioma · Bipolar I Depression

Sumitomo Pharma Co

Sumitomo Pharma (Suzhou) is a pharma organization headquartered in CN. Primary therapeutic focus areas include Malignant Pleural Mesothelioma, Bipolar I Depression, Carcinoma, Pancreatic Ductal, Bipolar Depression. NovaP

JP HQ
1897 Founded
193 Employees
NMPA registrant Type
Company details
Status
Public
HQ
JP
Founded
1897
Employees
193
Programs
4
Drugs
3
Patents
0
Clinical program

Placebo

Phase 3 · small molecule · Bipolar Depression

Placebo for Bipolar Depression is a Phase 3 program (small_molecule) at Sumitomo Pharma (Suzhou) Co., with 1 ClinicalTrials.gov record(s).

← All Sumitomo Pharma (Suzhou) Co., projects Phase 3 small molecule completed

Internal code D1002001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Sumitomo Pharma (Suzhou) Co.,
Phase
Phase 3
Modality
small_molecule
Indication
Bipolar Depression
Status
completed
Trials
1

Clinical trials